Key clinical point: Apremilast showed high efficacy in treating patients with recurrent aphthous stomatitis.
Major finding: Within 4 weeks of therapy, complete clearance of lesions was observed in the majority of patients.
Study details: A pilot study of 15 patients with recurrent aphthous stomatitis.
Disclosures: The study was supported by Celgene. The researchers reported having no financial disclosures.
Bruce AJ et al. AAD 20, Abstract 17701.